Loading clinical trials...

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 | Clinical Trials | Clareo Health

COMPLETED

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

NCT04314817•Groupe Hospitalier Pitie-Salpetriere

Summary

The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•all patients treated for Covid-19

Exclusion Criteria

•Chronology not compatible between the drug and the toxicity

Locations (1)

AP-HP Assistance Publique Hopitaux de Paris

Paris, France

Key Dates

Start Date

March 17, 2020

Primary Completion Date

January 1, 2023

Completion Date

January 1, 2023

Last Updated

April 21, 2023

Enrollment

1,000

ACTUAL participants

Conditions

CoronavirusIatrogenic DiseaseAcute Kidney InjuryARDS, Human

Interventions

Any drug used to treat Covid-19

DRUG

UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events

NCT05806645

Acute Kidney Injury

View study

RECRUITINGNA

Effects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat

NCT07472426

Acute Kidney InjuryExertional Heat Illness

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

Inclusion Criteria

Exclusion Criteria

UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events

Effects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients